MRT-2359
Monte Rosa Therapeutics
['mrt-2359']
monte rosa therapeutics presents preclinical data from gspt1 degrader program focused on myc-driven cancers at aacr 2023 - data demonstrate preferential activity of mrt-2359, an orally bioavailable gspt1-directed molecular glue degrader, in myc-driven t... 
CEO Of Digital Media Online